These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 25375953)

  • 1. Inhibitors of peptidyl proline isomerases as antivirals in hepatitis C and other viruses.
    Striker R; Mehle A
    PLoS Pathog; 2014 Nov; 10(11):e1004428. PubMed ID: 25375953
    [No Abstract]   [Full Text] [Related]  

  • 2. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
    Feld JJ; Hoofnagle JH
    Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The Past and Future of Hepatitis B Virus, Hepatitis C Virus, and Human Immunodeficiency Virus Infection].
    Hayashi J
    Rinsho Byori; 2015 Jun; 63(6):746-7. PubMed ID: 26548239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical shift assignments of the catalytic domain from the yeast proline isomerase Fpr4p.
    Monneau YR; Nelson CJ; Mackereth CD
    Biomol NMR Assign; 2012 Oct; 6(2):123-6. PubMed ID: 21898050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial.
    Simon DM; Gordon SC; Kaplan MM; Koff RS; Regenstein F; Everson G; Lee YM; Weiner F; Silverman A; Plasse T; Fedorczyk D; Liao MJ
    Hepatology; 1997 Feb; 25(2):445-8. PubMed ID: 9021962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C and autoimmunity.
    Wrobleski C; Friedman LS
    Gastroenterologist; 1996 Sep; 4(3):211-5. PubMed ID: 8891685
    [No Abstract]   [Full Text] [Related]  

  • 7. Prompt arrival of antivirals against hepatitis C for HIV patients.
    Barreiro P; Vispo E
    AIDS Rev; 2010; 12(4):242-3. PubMed ID: 21344779
    [No Abstract]   [Full Text] [Related]  

  • 8. [Interferon therapy for acute hepatitis C: evaluation by HCV antibody, HCV genotypes and serum RNA titer].
    Toyama H; Iwabuchi S
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):521-7. PubMed ID: 7563813
    [No Abstract]   [Full Text] [Related]  

  • 9. Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses.
    Tan H; Derrick J; Hong J; Sanda C; Grosse WM; Edenberg HJ; Taylor M; Seiwert S; Blatt LM
    J Interferon Cytokine Res; 2005 Oct; 25(10):632-49. PubMed ID: 16241862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does nitric oxide play a pathogenic role in hepatitis C virus infection?
    Majano PL; Garcia-Monzon C
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S13-5. PubMed ID: 12655339
    [No Abstract]   [Full Text] [Related]  

  • 12. Peptidyl-prolyl cis-trans isomerases: structure and functions.
    Pliyev BK; Gurvits BY
    Biochemistry (Mosc); 1999 Jul; 64(7):738-51. PubMed ID: 10424896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cytotoxic lymphocyte antigen 4 polymorphisms affect response to hepatitis C virus-specific therapy in HIV(+) patients with acute and chronic hepatitis C virus co-infection.
    Nischalke HD; Vogel M; Mauss S; Baumgarten A; Lutz T; Danta M; Naumann U; Coenen M; Sauerbruch T; Rockstroh JK; Spengler U; Nattermann J
    AIDS; 2010 Aug; 24(13):2001-7. PubMed ID: 20588168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stealth and cunning: hepatitis B and hepatitis C viruses.
    Wieland SF; Chisari FV
    J Virol; 2005 Aug; 79(15):9369-80. PubMed ID: 16014900
    [No Abstract]   [Full Text] [Related]  

  • 15. Liver histology in anti-HCV positive subjects with normal ALT levels.
    Puoti C; Stati T; Magrini A; Rigato P; Romagnoli G; Rossi P; Montagnese F; Resta S
    Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):383-4. PubMed ID: 9476196
    [No Abstract]   [Full Text] [Related]  

  • 16. [Hepatitis C virus infection--after 20 years].
    Pár A
    Orv Hetil; 2010 Mar; 151(12):485-93. PubMed ID: 20231132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for a vaccine against the hepatitis C virus.
    Houghton M; Abrignani S
    Nature; 2005 Aug; 436(7053):961-6. PubMed ID: 16107836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C virus vaccines--progress and perspectives.
    Fauvelle C; Lepiller Q; Felmlee DJ; Fofana I; Habersetzer F; Stoll-Keller F; Baumert TF; Fafi-Kremer S
    Microb Pathog; 2013 May; 58():66-72. PubMed ID: 23499591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statins and hepatitis C virus: more caution and less enthusiasm.
    Goldstein MR; Mascitelli L; Pezzetta F
    Am J Gastroenterol; 2008 Dec; 103(12):3207-8; author reply 3208-9. PubMed ID: 19086972
    [No Abstract]   [Full Text] [Related]  

  • 20. Challenges and successes in developing new therapies for hepatitis C.
    De Francesco R; Migliaccio G
    Nature; 2005 Aug; 436(7053):953-60. PubMed ID: 16107835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.